Treatment with
VariableImmune/Antibody
W
View full entry on WUSTL Neuromuscular
antibody/motpn2.htm#rx
Overview
From WUSTL Neuromuscularcyclophosphamidehuman immune globulin (HIG) Improvement in strength after treatment with HIG (for example 1 g/kg/day x 2 days) is common (50% to 70% of cases), but the length of benefit is variable, lasting from 2 weeks to 6 or more months. The dose and frequency of subsequent treatments is based on individual patient response. 1. The period of maximum improvement after HIG treatment should be monitored. Subsequent treatments should be given just before a relapse is expected. The minimum effective dose of HIG can be determined by sequentially reducing the subsequent HIG doses by 10% until a le
Related Conditions
Shared genesAcute Motor (Axonal) Neuropathy (AMAN)
IIGQ1BGM1
Antibodies vs Glycolipids & Glycoproteins
GM1MAGGQ1B
C. Anti-GM1 Antibodies
GM1IGMGM1LMN
Chronic Immune Demyelinating Neuropathies: Variants
GD1AMOTORGM1
Features of motor syndromes: Likely response to therapy
GM1
Guillain-Barré-like syndrome with serum IgM binding to GalNAc-GD1a ganglioside
GD1AGM1PATHOLOGY
Lower Motor Neuron Syndrome: Proximal Arm Predominant 1,
GM1
Motor neuropathy-Motor neuron syndromes
GM1
External Resources
Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.